On February 5, 2026, the independently developed recombinant chorionic gonadotropin (rhCG) for female animal reproduction by Beijing VJTBio Co., Ltd. officially received approval from China's Ministry of Agriculture and Rural Affairs, obtaining a National New Veterinary Drug Certificate for use in sow reproduction. As the world's first recombinant hCG specifically developed for female animal reproduction, this product precisely targets the ovaries, efficiently inducing mature follicles in sows to ovulate in a concentrated manner, and is highly suited to the demands of modern large-scale batch farming. Compared with traditional extracted products, this product offers three core advantages: higher specific activity, consistent batch quality, and controllable cost, providing a more precise and efficient reproductive regulation solution. Meanwhile, VJTBio is accelerating the expansion of this product's applications to cover cattle, sheep, and aquaculture reproduction, committed to providing efficient, stable, safe, green, and full-scenario reproductive management solutions for the intensive animal farming industry, supporting the scaled and standardized high-quality development of animal husbandry.

Ending Urine-Derived Hormones: China's "Dual Recombinant" Protein Hormone Combination Breaks New Ground in Sow Reproductive Management

Currently, the commonly used drugs for inducing ovulation in female animals fall mainly into two categories: urine-derived hCG and gonadotropin-releasing hormone (GnRH) analogs, both of which have application pain points. Urine-derived hCG originates from pregnant women's urine. Due to raw material limitations, it suffers from significant batch-to-batch quality variation and high costs, directly affecting reproductive outcomes. GnRH analogs, synthesized as small peptides, act indirectly through the pituitary gland. Their effectiveness is easily influenced by individual pituitary function and depends on a "pulsatile secretion" regulatory pattern, presenting uncertainties and limitations in practical application.

VJTBio has broken through these challenges with recombinant technology, successfully developing and launching the world's first recombinant hCG specifically for female animal reproduction, achieving a product upgrade in the field of ovulation induction in female animals. Unlike traditional drugs, this product acts directly on the ovaries, precisely simulating the endogenous "LH surge," aligning with the natural ovulatory physiology of female animals, enabling efficient, stable, and precise ovulation induction. Importantly, this product works in synergy with the company's National Class I New Veterinary Drug, i.e., "Recombinant Porcine Follitropin Fc Fusion Protein for Injection", forming a cornerstone product portfolio for reproductive regulation in large-scale farming. This combination fully covers the precise reproductive regulation process from follicle development to ovulation. Data from large-scale batch farming studies involving tens of thousands of sows show that compared with traditional hormones, relying on VJTBio's integrated reproductive solutions ensures that replacement gilts complete at least two estrous cycles before 220 days of age, achieving a mating participation rate of 92-95%, reducing rearing costs for herd entry. For multiparous sows, it increases the 7-day weaning-to-mating rate by 10%, improves overall batch participation rate by 6-8%, increases the number of healthy piglets per litter by 0.5-1 head, and raises the number of pigs weaned per sow per year (PSY) by 2 head, precisely achieving dual improvements in reproductive performance for both replacement gilts and multiparous sows. By reducing feeding costs, increasing production capacity, and decreasing disease-related losses, ROI reaches 1:6, helping the farming industry transition to a low-cost, high-efficiency, safe, and green modern batch production model.

HighHigh Specific Activity, Consistent Quality, Controllable Cost: VJTBio's Three-Dimensional Breakthrough in the Global Animal Health Recombinant Chorionic Gonadotropin Industrialization

hCG, as a heterodimer, is formed by the connection of α and β subunits through weak van der Waals forces. It also features complex glycosylation modifications, making its structure easily affected by temperature, ions, and other factors, leading to oxidation, aggregation, and reduced activity. In the biopharmaceutical field, the development of recombinant hCG has long faced multiple technical challenges. The core bottlenecks include: first, the difficulty in efficiently expressing recombinant proteins with correct spatial structure and adequate glycosylation modifications in recombinant expression systems; second, the loss of target product yield during downstream purification to remove inactive and low-activity impurities, making it difficult to balance "quality-efficiency-cost," a key challenge constraining its industrialization.

Leveraging its self-established core technology platform for recombinant protein hormone drug development, VJTBio has overcome the technical barriers to recombinant hCG industrialization through systematic process optimization. In the upstream stage, by optimizing cell culture media formulations and parameters, the company harvests recombinant molecules with correct spatial structure that closely resemble natural hCG. In the downstream stage, innovative chromatographic separation technology precisely removes inactive and low-activity impurities, achieving a balance of high yield, high purity, and cost control. Formulation has also been optimized to comprehensively ensure the stability of recombinant hCG across various application scenarios. The final product exhibits specific activity more than 20% higher than that of internationally leading human recombinant hCG, highlighting the product's core technological edge.

With its proprietary recombinant protein hormone drug development technology platform as the foundation, VJTBio has systematically solved the challenges of recombinant hCG industrialization. While strictly ensuring high product quality, the company has achieved cost controllability, truly providing the farming industry with high-quality, affordable, and easily scalable recombinant chorionic gonadotropin products, further solidifying its vision of leadership position in the field of animal recombinant drugs.

Multi-Species Coverage: Driving Modernization of Animal Health with Precision Reproductive Technology

As a major farming nation, China has 30 million fertile cows and 115 million fertile ewes. In the process of modern large-scale farming, the industry still faces common challenges such as low conception rates and insufficient adoption of batch reproductive technologies, which consistently constrain efforts to improve quality and efficiency in animal husbandry. Based on its self-developed recombinant FSH and recombinant hCG reproductive regulation product portfolio, VJTBio provides efficient and stable reproductive regulation solutions for intensive farming, powerfully supporting the transition of livestock production toward standardized and modernized systems. In aquaculture reproduction, traditional urine-derived hCG suffers from low specific activity and large batch variation, leading to high practical dosages and costs. Recombinant hCG, with its core advantages of high purity, high specific activity, and stable quality, significantly reduces the required dosage and addresses more aquaculture challenges. Currently, VJTBio is accelerating the expansion of recombinant hormone applications to cattle, sheep, and aquaculture, with relevant clinical trials underway. In the future, the company will provide targeted, highly adaptable reproductive regulation solutions for different livestock and aquatic species, continuously empowering the high-quality development of China's livestock and aquaculture industries.

Reproduction and breeding are vital pillars of national agricultural security and form the cornerstone for ensuring green, safe, zero-residue, high-quality meat, eggs, and milk for the public. VJTBio is deeply committed to the field of recombinant protein drugs, developing cornerstone products that support reproduction, breeding, and agricultural security. Aligned with national strategic needs, the company has undertaken two key research projects under the 14th Five-Year National Key R&D Program, focusing on the core technological challenges of efficient batch production in sows and rapid multiplication in cows, driving quality, efficiency, cost savings, and consumption reduction in animal husbandry through technological innovation. In the future, VJTBio will continue to work diligently and strive for excellence, rooted in China while reaching out globally, to strengthen the foundation of national agricultural security and help the livestock and poultry farming industry steadily progress toward a green, healthy, and efficient high-quality development path.